Hemostemix Inc. (HEM.V)
| Previous Close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.1500 x 0 |
| Ask | 0.1550 x 0 |
| Day's Range | 0.1500 - 0.1500 |
| 52 Week Range | 0.1150 - 0.4200 |
| Volume | |
| Avg. Volume | 71,290 |
| Market Cap | 11.361M |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2410 |
| Earnings Date | Sept 26, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.96 |
- Newsfile
Hemostemix Closes $762,400 of The Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it has closed its first tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of $762,400 (the "Offering"). The Offering consisted of the issuance of an aggregate of 3,812,000 Units at a price of $0.20 per Unit.Each Unit consists of one common share in ...
- Newsfile
Hemostemix Unit Offering Repriced
Calgary, Alberta--(Newsfile Corp. - March 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) announces it is repricing its offering of 14 Million Common Share Units to $0.20 each. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.65 per ...
- Newsfile
Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval
Calgary, Alberta--(Newsfile Corp. - March 7, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("HEM" or the "Company") is pleased to announce it is selling up to 500 five-year 6% unsecured convertible debentures ("CD") at USD $35,000 each. The CD can be converted into one of 500 ACP-01 therapeutic production slots ("TPS"), subject to patients' compassionate exemption from regulatory approval, or is convertible into Common Shares of Hemostemix as ...
